Mirum Pharmaceuticals, a fast-growing biopharmaceutical firm, is on a mission to tackle rare and orphan ailments, with LIVMARLI serving as its flagship product candidate. The investigational oral drug has been effectively developed to alleviate the symptoms of progressive familial intrahepatic cholestasis disease, Alagille syndrome, and biliary atresia disease. The California-based company's Volixibat drug, on the other hand, represents a promising treatment option for primary sclerosing cholangitis and primary biliary cholangitis in adults. Since it was founded in 2018, the company has shown remarkable dedication to achieve its goals.